Zurcher Kantonalbank Zurich Cantonalbank Raises Stake in Insulet Co. (NASDAQ:PODD)

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Insulet Co. (NASDAQ:PODD) by 15.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,319 shares of the medical instruments supplier’s stock after buying an additional 5,031 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.05% of Insulet worth $8,686,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. increased its stake in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the period. International Assets Investment Management LLC purchased a new stake in Insulet in the second quarter valued at $32,000. Venturi Wealth Management LLC grew its position in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares during the period. UMB Bank n.a. raised its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares during the last quarter. Finally, CVA Family Office LLC lifted its holdings in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the period.

Insulet Price Performance

NASDAQ:PODD opened at $266.78 on Monday. The stock has a 50 day moving average of $244.40 and a two-hundred day moving average of $214.14. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The firm has a market cap of $18.71 billion, a P/E ratio of 45.68, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PODD. Citigroup raised their target price on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective on the stock. UBS Group boosted their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Barclays increased their price target on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Canaccord Genuity Group lifted their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.